期刊
JOURNAL OF DRUG TARGETING
卷 27, 期 2, 页码 111-124出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2018.1473409
关键词
alpha(v)beta(3) integrin receptors; cRGD; targeting; nanocarriers; cancer
资金
- Science and Engineering Research Board (SERB), New Delhi, India
The integrins alpha(v)beta(3) play a very imperative role in angiogenesis and are overexpressed in endothelial cells of the tumour. Recent years have witnessed huge exploration in the field of alpha(v)beta(3) integrin-mediated bioactive targeting for treatment of cancer. In these studies, the cRGD peptide has been employed extensively owing to their binding capacity to the alpha(v)beta(3) integrin. Principally, RGD-based approaches comprise of antagonist molecules of the RGD sequence, drug-RGD conjugates, and most importantly tethering of the nanocarrier surface with the RGD peptide as targeting ligand. Targeting tumour vasculature or cells via cRGD conjugated nanocarriers have emerged as a promising technique for delivering chemotherapeutic drugs and imaging agents for cancer theranostics. In this review, primary emphasis has been given on the application of cRGD-anchored nanocarriers for targeted delivery of drugs, imaging agents, etc. for tumour therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据